Vantage logo

Neurocrine voyages into gene therapy 

A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.

Vantage logo

Round two for Axsome

Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.